OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort

Cancer Biomarkers

Volumn 10, Issue 5, 2011, Pages 233-239

  Xu, Qian ^a   Yuan, Bibo ^a   Xue, Fengxia ^a   Zhang, Linqin ^a   Li, Jie ^a   Guo, Hualing ^a   Yue, Tianfu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cervical cancer; Osteopontin; Polymorphisms; risk

Indexed keywords

OSTEOPONTIN;

ADULT; ARTICLE; CANCER INVASION; CANCER RISK; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; UTERINE CERVIX CANCER;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84862890125     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0251     Document Type: Article

References (33)

1. W. Prendiville, Risk of cancer in women with cervical precancer: improving risk assessment and management protocols. Cytopathology 22 (2011) 143-145.
2. A. Ibrahim, V. Rasch, E. Pukkala, A.R. Aro, Cervical cancer risk factors and feasibility of visual inspection with acetic acid screening in Sudan. Int J Womens Health 3 (2011) 117-122.
3. X. Zhang, B. Dai, B. Zhang, Z. Wang, Vitamin A and risk of cervical cancer: A meta-analysis. Gynecol Oncol (2011).
4. A.M. Nowakowski, J. Kotarski, Risk factors of cervical cancer and possibilities of primary prevention. Przegl Epidemiol 65 (2011) 81-88.
5. H.A. Katki, W.K. Kinney, B. Fetterman, T. Lorey, N.E. Poitras, L. Cheung, F. Demuth, M. Schiffman, S. Wacholder, P.E. Castle, Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12 (2011) 663-672.
6. S.S. Han, E.Y. Cho, T.S. Lee, J.W. Kim, N.H. Park, Y.S. Song, J.G. Kim, H.P. Lee, S.B. Kang, Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical cancer in Korean women. Eur J Obstet Gynecol Reprod Biol 140 (2008) 71-75.
7. R. Catarino, A. Matos, D. Pinto, D. Pereira, R. Craveiro, A. Vasconcelos, C. Lopes, R. Medeiros, Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 160 (2005) 49-54. (Pubitemid 40798136)
8. A. Acikgoz, G. Ergor, Cervical cancer risk levels in Turkey and compliance to the national cervical cancer screening standard. Asian Pac J Cancer Prev 12 (2011) 923-927.
9. G. Mastrangelo, G.Marangi, M.N. Ballarin, S. Michilin, A.S. Fabricio, F. Valentini, J.H. Lange, U. Fedeli, L. Cegolon, M. Gion, Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study. BMC Public Health 11 (2011) 220.
10. C. Hunter, J. Bond, P.C. Kuo, M.A. Selim, H. Levinson, The Role of Osteopontin and Osteopontin Aptamer (OPN-R3) in Fibroblast Activity. J Surg Res (2011).
11. A. Baroni, A. De Filippis, E. Buommino, R.A. Satriano, V. Cozza, Osteopontin, a protein with cytokine-like properties: a possible involvement in pemphigus vulgaris. Arch Dermatol Res (2011).
12. X.Q. Zhao, J.H. Dong, W.Z. Zhang, Z. Liu, Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagn Pathol 6 (2011) 98.
13. R. Zhang, X. Pan, Z. Huang, G.F. Weber, G. Zhang, Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 6 (2011) e23831.
14. S. Isa, T. Kawaguchi, S. Teramukai, K. Minato, Y. Ohsaki, K. Shibata, T. Yonei, K. Hayashibara, M. Fukushima, M. Kawahara, K. Furuse, P.C. Mack, Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4 (2009) 1104-1110.
15. Y. Li, L. Li, J.T. Wang, X. Kan, J.G. Lu, Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol (2011).
16. W. Sieghart, X. Wang, K. Schmid, M. Pinter, F. Konig, M. Bodingbauer, F. Wrba, S. Rasoul-Rockenschaub, M. Peck- Radosavljevic, Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 54 (2011) 89-97.
17. L. Ding, S. Zheng, Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues. Zhonghua Wai Ke Za Zhi 40 (2002) 773-775.
18. L. Ding, S. Zheng, J. Cao, Expression of osteopontin mRNA and its protein in colorectal cancer and liver metastatic tissues. Zhonghua Yi Xue Za Zhi 82 (2002) 970-973.
19. H.L. Ke, L.L. Chang, S.F. Yang, H.H. Lin, C.C. Li, D.C. Wu, W.J.Wu, Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol (2009).
20. H. Matsuzaki, K. Shima, T. Muramatsu, Y. Ro, S. Hashimoto, T. Shibahara, M. Shimono, Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 36 (2007) 30-34. (Pubitemid 44973985)
21. Y. Shimada, G. Watanabe, J. Kawamura, T. Soma, M. Okabe, T. Ito, H. Inoue, M. Kondo, Y. Mori, E. Tanaka, M. Imamura, Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68 (2005) 285-292. (Pubitemid 41158988)
22. H. Cho, E.S. Kang, Y.T. Kim, J.H. Kim, Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 27 (2009) 313-323.
23. Y. Hashiguchi, H. Tsuda, C.A. Bandera, S. Nishimura, T. Inoue, N. Kawamura, R.S. Berkowitz, S.C.Mok, Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol 23 (2006) 205-212. (Pubitemid 43780303)
24. P. Sharma, S. Kumar, G.C. Kundu, Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 9 (2010) 178.
25. J.Y. Song, J.K. Lee, N.W. Lee, B.W. Yeom, S.H. Kim, K.W. Lee, Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol 49 (2009) 434-438.
26. H. Cho, S.W. Hong, Y.J. Oh, M.A. Kim, E.S. Kang, J.M. Lee, S.W. Kim, S.H. Kim, J.H. Kim, Y.T. Kim, K. Lee, Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 134 (2008) 909-917.
27. Y.W. Chiu, H.F. Tu, I.K. Wang, C.H. Wu, K.W. Chang, T.Y. Liu, S.Y. Kao, The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 46 (2010) 302-306.
28. Y.S. Chang, H.J. Kim, J. Chang, C.M. Ahn, S.K. Kim, Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57 (2007) 373-380. (Pubitemid 47285428)
29. J. Schultz, P. Lorenz, S.M. Ibrahim, G. Kundt, G. Gross, M. Kunz, The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 48 (2009) 14-23.
30. P. Cinek, V. Stibor, TNM classification of malignant ocular tumors . Cesk Slov Oftalmol 60 (2004) 408-415. (Pubitemid 39578295)
31. F. Giacopelli, R. Marciano, A. Pistorio, P. Catarsi, S. Canini, G. Karsenty, R. Ravazzolo, Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20 (2004) 87-96.
32. Y. Saitoh, J. Kuratsu, H. Takeshima, S. Yamamoto, Y. Ushio, Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72 (1995) 55-63.
33. J. Sodek, B. Ganss, M.D. McKee, Osteopontin. Crit Rev Oral Biol Med 11 (2000) 279-303.